Genprex Inc. (NASDAQ: GNPX) Pioneering an Innovative Cancer Therapy, Preclinical Data Shows Positive Results
- Gene therapy could help overcome barriers that currently stand in the way of a cure for cancer
- Genprex is developing innovative, gene-based approaches toward the treatment of cancer, specifically non-small cell lung cancer
- Clinical trials so far have yielded encouraging data regarding the efficacy and safety of the company’s product candidate, Oncoprex
Gene therapy could potentially advance the creation and delivery of effective cancer treatments in the years to come. Various companies are leading the way, and pioneers such as Genprex Inc. (NASDAQ: GNPX) are pushing for the introduction of innovative and targeted therapies that have the potential to help patients with various malignancies.
Gene therapy refers to the therapeutic delivery of DNA or RNA to the cells of a patient for the purpose of treating a disease. It was first conceptualized in 1972, and some of the first successful gene therapy trials took place in the 1990s (http://nnw.fm/p7Ffm).
Today, Genprex is working on an innovative, gene therapy-based approach for the treatment of non-small cell lung cancer (NSCLC). The company’s initial product candidate is called Oncoprex immunogene therapy, and it encapsulates a tumor suppressor gene (TUSC2) that is delivered through cholesterol nanoparticles.
Oncoprex is administered intravenously. According to Genprex CEO Rodney Varner, Oncoprex allows a systemic and targeted approach toward the treatment of NSCLC, because the nanoparticles are attracted to the cancer cells like a magnet.
Once Oncoprex reaches the cancer cells, TUSC2 is expressed into a protein that restores some of the defective gene functions arising in cancer cells, and the nanoparticles are taken up at a rate that’s up to 25-times higher than in the case of normal cells.
Research suggests that Oncoprex is synergistic with targeted and immunotherapies, and research has also shown that Oncoprex delivers results in several ways. It interrupts the proliferation of cancer cells, helps cancer cell death and modulates the immune response against cancer cells. In addition, Oncoprex blocks mechanisms that can contribute to drug resistance and has demonstrated minimal side effects compared to other lung cancer drugs.
Currently, Genprex holds more than 30 patents for its platform technologies. The company has also recruited renowned scientists, forming a powerful team that features some of the brightest minds in biotech, oncology and clinical research.
Genprex is now conducting the second phase of a phase I/II clinical trial. It also plans to expand its pipeline through the addition of a new clinical study that evaluates the effectiveness of Oncoprex in combination with a checkpoint inhibitor for the treatment of NSCLC.
NSCLC is the most common type of lung cancer. It accounts for approximately 85 percent of all lung cancer cases and, despite the development of innovative treatment strategies, the survival rate for lung cancer patients has not improved significantly over the past 25 years (http://nnw.fm/0YVIu).
Breakthrough technologies and therapeutic approaches like those developed by Genprex could take cancer treatment solutions to a new level of effectiveness. Gene therapy could be the one innovative development that will contribute to curing what’s currently incurable, and companies like Genprex are spearheading these efforts.
For more information, visit the company’s website at www.Genprex.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Gene therapy could help overcome barriers that currently stand in the way of a cure for cancer
- Genprex is developing innovative, gene-based approaches toward the treatment of cancer, specifically non-small cell lung cancer
- Clinical trials so far have yielded encouraging data regarding the efficacy and safety of the company’s product candidate, Oncoprex
Gene therapy could potentially advance the creation and delivery of effective cancer treatments in the years to come. Various companies are leading the way, and pioneers such as Genprex Inc. (NASDAQ: GNPX) are pushing for the introduction of innovative and targeted therapies that have the potential to help patients with various malignancies.
Gene therapy refers to the therapeutic delivery of DNA or RNA to the cells of a patient for the purpose of treating a disease. It was first conceptualized in 1972, and some of the first successful gene therapy trials took place in the 1990s (http://nnw.fm/p7Ffm).
Today, Genprex is working on an innovative, gene therapy-based approach for the treatment of non-small cell lung cancer (NSCLC). The company’s initial product candidate is called Oncoprex immunogene therapy, and it encapsulates a tumor suppressor gene (TUSC2) that is delivered through cholesterol nanoparticles.
Oncoprex is administered intravenously. According to Genprex CEO Rodney Varner, Oncoprex allows a systemic and targeted approach toward the treatment of NSCLC, because the nanoparticles are attracted to the cancer cells like a magnet.
Once Oncoprex reaches the cancer cells, TUSC2 is expressed into a protein that restores some of the defective gene functions arising in cancer cells, and the nanoparticles are taken up at a rate that’s up to 25-times higher than in the case of normal cells.
Research suggests that Oncoprex is synergistic with targeted and immunotherapies, and research has also shown that Oncoprex delivers results in several ways. It interrupts the proliferation of cancer cells, helps cancer cell death and modulates the immune response against cancer cells. In addition, Oncoprex blocks mechanisms that can contribute to drug resistance and has demonstrated minimal side effects compared to other lung cancer drugs.
Currently, Genprex holds more than 30 patents for its platform technologies. The company has also recruited renowned scientists, forming a powerful team that features some of the brightest minds in biotech, oncology and clinical research.
Genprex is now conducting the second phase of a phase I/II clinical trial. It also plans to expand its pipeline through the addition of a new clinical study that evaluates the effectiveness of Oncoprex in combination with a checkpoint inhibitor for the treatment of NSCLC.
NSCLC is the most common type of lung cancer. It accounts for approximately 85 percent of all lung cancer cases and, despite the development of innovative treatment strategies, the survival rate for lung cancer patients has not improved significantly over the past 25 years (http://nnw.fm/0YVIu).
Breakthrough technologies and therapeutic approaches like those developed by Genprex could take cancer treatment solutions to a new level of effectiveness. Gene therapy could be the one innovative development that will contribute to curing what’s currently incurable, and companies like Genprex are spearheading these efforts.
For more information, visit the company’s website at www.Genprex.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
